DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program

$DVA
Misc Health and Biotechnology Services
Health Care
Get the next $DVA alert in real time by email

Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patients

DENVER, Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes in the U.S., DaVita commends the efforts from likeminded specialty care providers leading the movement.

These efforts have helped lead the kidney care community through scaled participation and investment in these programs, which are part of the Comprehensive Kidney Care Contracting (CKCC) option within the government's voluntary Kidney Care Choices (KCC) model — a value-based care demonstration that began on Jan. 1, 2022, as the largest government model for kidney care.

"This program relies on the understanding that kidney care in the U.S. has been fragmented and that a system that better coordinates these care silos is better for our patients. When our patients do better, they can live a better life and cost the system less money. Those savings can be wrapped around to provide even better care — and the cycle continues," said Dr. Gregory Spin, clinical leader for the Northern California Kidney Care Choices group and founding partner of Summit Nephrology. "We have worked hard to share best practices across our program, and DaVita has amplified that process by bringing learnings from other participants."

Together with participating nephrologists, DaVita launched 11 value-based care arrangements in 2022 and has since doubled that footprint to 22 Kidney Contracting Entities (KCEs). An evaluation now available for the first performance year (PY1) demonstrates that these value-based care arrangements result in better patient outcomes, which, over time, should lead to decreasing cost expenditures. This includes engaging patients in their care earlier and supporting access to kidney transplants for patients managing their kidney health.

Physicians and providers in the CKCC program improved outcomes for patients through collective quality metrics, with a 16% industry increase in optimal start rates for kidney patients transitioning to dialysis. Reducing unplanned starts leads to more optimal outcomes for patients, with care teams better coordinating their kidney and non-kidney care needs as well as improving interventions to help keep them healthy and out of the hospital, while also reducing high health care costs.

"Our focus at the launch of the program was to provide robust support for our nephrology partners, and we're encouraged by the current momentum. Though scaled transformation takes time, we continue to trend positively into the third year of the program," said Dr. Amy Schuerman-Gen, chief medical officer for DaVita Integrated Kidney Care (DaVita IKC). "Our vision for care innovation is taking shape, with CKCC laying a vital foundation for lasting change. The model's emphasis on care coordination and patient engagement has already led to encouraging health outcomes, and we're optimistic about the program's potential for continued success."

DaVita and its nephrologist partners have already seen significant progress over the course of the CKCC program and expect the impact on outcomes and cost savings will continue to improve. Achievements include:

  • Embedding care team members in 68% of nephrology practices, providing care to shared patients directly at the site of care.
  • Overseeing approximately 31,000 patients across dialysis centers of multiple providers, remotely, and in nephrologist offices.
  • Enabling 2.4x more DaVita patients to have a planned start on home treatment through patient education, care management and transition support.
  • Screening 67% of patients for depression remission with a baseline PHQ-9 across 11 KCEs, supporting holistic care of both physical and mental health.
  • Increasing patient activation by 13%, indicating higher patient engagement across patient populations — inclusive of people with chronic kidney disease (CKD) and people with end-stage kidney disease (ESKD) who do not treat at DaVita.

Care coordination is fueled in part by DaVita's tech-enabled platform, with more than half of participants either leveraging DaVita's co-designed EHR with Epic or allowing DaVita access to another platform. This foundation helps to meet patients earlier with crucial identification and education to help slow progression to kidney failure and avoid dialysis. From PY1 to current year-to-date, DaVita has increased CKD education by 39% via Kidney Smart®, an award-winning, interactive community and virtual education program, for patients aligned with CKCC practices.

From coast to coast, participation in CKCC has allowed for a broad evaluation of the positive impact value-based care at scale can have for kidney patients.

"As we continue in the CKCC demonstration, I look forward to working collaboratively with our DaVita IKC partners and others to tackle difficult challenges we face in patient-centered care," said Dr. Alec Otteman of Associated Nephrology Consultants in St. Paul, MN. "We continue to work through how to best support patients to prevent hospitalizations and readmissions, and our DaVita IKC partners can create wrap-around support for medication reconciliation and transition of care post-hospitalization."

For more information about DaVita IKC's programs and results, visit DaVita.com/IKC 

About DaVita Inc.

DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Forward-Looking Statements 

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially from these forward-looking statements, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release, except as may be otherwise required by law.

The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

Media Contact:

DaVita Newsroom

newsroom@davita.com 

DaVita Logo (PRNewsfoto/DaVita)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-celebrates-kidney-care-community-achievements-in-year-one-of-largest-ever-value-based-care-program-302282733.html

SOURCE DaVita

Get the next $DVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What recent announcement has DaVita made regarding their kidney care initiatives for Medicare patients?

    DaVita has announced significant clinical outcomes achieved through the CKCC program which launched in 2022, aimed at improving kidney care for Medicare patients.

  • What specific improvement in patient outcomes has been observed in the CKCC program?

    The CKCC program has seen participants report a 16% increase in optimal starting rates for kidney patients transitioning to dialysis, leading to improved outcomes.

  • How many Kidney Contracting Entities (KCEs) has DaVita launched as part of their value-based care arrangements?

    DaVita and participating nephrologists have doubled their footprint from 11 to 22 Kidney Contracting Entities (KCEs) within the CKCC program since its inception.

  • What change in patient engagement has been reported in the CKCC program?

    Patient engagement and activation have increased by 13% among CKD and ESKD patients, illustrating improved engagement in their health care.

  • How is technology being leveraged within the CKCC program to improve patient education and care coordination?

    The CKCC program utilizes a tech-enabled platform to enhance care coordination, which has led to a 39% increase in CKD education through DaVita's Kidney Smart program.

Recent Analyst Ratings for
$DVA

DatePrice TargetRatingAnalyst
3/6/2024$133.00Equal Weight
Barclays
8/7/2023$100.00 → $142.00Neutral → Buy
UBS
11/1/2022$97.00 → $72.00Buy → Hold
Deutsche Bank
10/31/2022$117.00 → $74.00Buy → Neutral
UBS
8/19/2022$106.00 → $117.00Buy
UBS
6/21/2022$110.00 → $90.00Underperform
BofA Securities
1/5/2022$114.00 → $125.00Hold
Truist Securities
10/29/2021$113.00 → $111.00Sector Perform
RBC Capital
More analyst ratings

$DVA
Press Releases

Fastest customizable press release news feed in the world

See more
  • DaVita Inc. 4th Quarter 2024 Results

    DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

    DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Celebrates 25 Years of Exceptional Patient Care, Empowering the Future of Kidney Health

    DENVER, Jan. 15, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care provider, is celebrating 25 years of clinical care delivery and leadership in healthcare innovation. Since forming with a purpose "to give life" in 2000, DaVita has focused its efforts to improve clinical outcomes, enhance quality of life for patients and be a force for positive change for the healthcare system. By fostering an inclusive, mission-driven workforce and building strong community partnerships, DaVita is helping empower the future of kidney health. DaVita's 25 years of clinical excellence is built on a steadfast commitment to patient-centered care — through purpose-driven clinical strategy, value-based prog

    $DVA
    Misc Health and Biotechnology Services
    Health Care

$DVA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DVA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DVA
SEC Filings

See more

$DVA
Leadership Updates

Live Leadership Updates

See more
  • DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    $DVA
    Misc Health and Biotechnology Services
    Health Care

$DVA
Financials

Live finance-specific insights

See more
  • DaVita Inc. 4th Quarter 2024 Results

    DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

    DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to

    $DVA
    Misc Health and Biotechnology Services
    Health Care
  • DaVita Inc. 3rd Quarter 2024 Results

    DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quarter ended September 30, 2024: Consolidated revenues were $3.264 billion.Operating income was $535 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.

    $DVA
    Misc Health and Biotechnology Services
    Health Care

$DVA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more